[
  {
    "sentence": "IO trials from the United States had stable growth, while the numbers of IO trials from Asia and Europe were observed to have decreasing trends of −32% and −8% in 2012 to 2015, although they increased thereafter (Figure 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Multinational IO trials had the second greatest proportions of trials for ICIs and multiple IO therapies, while European countries had the greatest proportions of trials for cancer vaccines and immune modulators (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "IO trials from the United States had stable growth, while the numbers of IO trials from Asia and Europe were observed to have decreasing trends of −32% and −8% in 2012 to 2015, although they increased thereafter (Figure 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Multinational IO trials had the second greatest proportions of trials for ICIs and multiple IO therapies, while European countries had the greatest proportions of trials for cancer vaccines and immune modulators (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In the assessment of corticosteroid‐related criteria, the ranking of trials in the five IO categories in order from most to least strict was as follows: ICIs, multiple IO therapies, cancer vaccines, ACT and immune modulators (Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The most stringent limitations regarding infection were found in ICI trials, followed by those studying multiple IO therapies, especially in terms of TB (34.6% and 17.6%) and pneumonitis/pneumonia (51.7% and 31.8%) (Figure 4B; Table S1).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Second, our study showed that the curves depicting the publication of IO trials in different subgroups (Figure 5) were only significantly separated in the third year.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Second, our study showed that the curves depicting the publication of IO trials in different subgroups (Figure 5) were only significantly separated in the third year.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  }
]